FDA Reviews Samsung Bioepis’ Bevacizumab
Avastin Rival Will Be Sold Through Merck, Sharp & Dohme
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.